Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.50 |
| ▸ | NOS1 | P29475 | 10/20 | 0.50 |
| ▸ | NOS3 | P29474 | 7/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664511 | 0.90 | NOS2 (0.58) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL4663075 | 0.85 | NOS2 (0.52) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL4664441 | 0.85 | NOS2 (0.52) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5041160 | 0.85 | NOS2 (0.58) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036501 | 0.83 | NOS2 (0.70) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL4664600 | 0.83 | NOS2 (0.59) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036437 | 0.83 | NOS2 (0.58) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL4663083 | 0.82 | NOS2 (0.52) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036602 | 0.82 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| Dimethylamine SCHEMBL5033922 | 0.82 | NOS2 (0.68) | NOS2NOS1NOS3CYP2C9FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673371-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080125460-A1 | Imidazopyridine-Derivatives As Inducible No-Synthase Inhibitors | ALTANA PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125460-A1 | Imidazopyridine-Derivatives As Inducible No-Synthase Inhibitors | PTGS1, PTGIS, NOS1 | NOS2 4/4885NOS1 3/4885NOS3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.